Government strengthens support for melanoma patients with breakthrough treatment expanded on PBS

Australian Government

1 March 2020 - The start of autumn will bring with it a new sense of hope for over 2,000 Australians with advanced melanoma, with the Australian Government expanding subsidised access to breakthrough melanoma treatment options on the Pharmaceutical Benefits Scheme from today.

On March 1, the current PBS listing of Opdivo (nivolumab) will be expanded to include adjuvant treatment of completely resected stage IIIB, IIIC, IIID and stage IV malignant melanoma.

The Government is also expanding the listing of Opdivo and Yervoy (nivolumab and ipilimumab) to allow use as a first-line therapy in the treatment of BRAF V600 mutant positive Stage III or Stage IV unresectable or metastatic melanoma.

Read Minister of Health press release

Michael Wonder

Posted by:

Michael Wonder